High-dose chemotherapy with carmustine, etoposide, cytarabine and melphalan followed by autologous stem cell transplant is an effective treatment for elderly patients with poor-prognosis lymphoma

Leukemia and Lymphoma

Volumn 56, Issue 8, 2015, Pages 2379-2387

  Martin, Nicolas ^a   Borchiellini, Delphine ^a   Coso, Diane ^b   Gastaud, Lauris ^a   Boscagli, Annick ^a   Saudes, Laurence ^c   Re, Daniel ^d   Gutnecht, Jean ^e   Garnier, Georges ^f   Petit, Emmanuel ^g   Barriere, Jèrôme ^h   Naman, Hervé ⁱ   Rossignol, Benoit ^j   Thyss, Antoine ^a   Peyrade, Frederic ^a  

^a CENTRE ANTOINE LACASSAGNE   (France)

^b INSTITUT PAOLI CALMETTES   (France)

^c Cannes Hospital   (France)

^d CHG Antibes Juan les Pins   (France)

^e Department of Oncology Frejus Saint Raphael Hospital   (France)

^f Princesse Grace Hospital Center   (Monaco)

^g Department of Oncology Oxford Clinic   (France)

^h Clinique Saint Jean   (France)

ⁱ Azurean Center of Oncology   (France)

^j La Dracenie Hospital Center   (France)

more..

Author keywords

Autologous stem cell transplant; BEAM; elderly; lymphoma

Indexed keywords

BICARBONATE; BUSULFAN; CARBOPLATIN; CARMUSTINE; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FILGRASTIM; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; IBRITUMOMAB TIUXETAN; MELPHALAN; PLERIXAFOR; PREDNISONE; RANIMUSTINE; RITUXIMAB; THIOTEPA; VANCOMYCIN; VINCRISTINE; ANTINEOPLASTIC AGENT;

AGED; ANEMIA; ARTICLE; ATRIAL FIBRILLATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CEREBROVASCULAR DISEASE; CLINICAL ASSESSMENT; COMORBIDITY; DIABETES MELLITUS; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; FEMALE; FEVER; GASTROINTESTINAL DISEASE; HEART ATRIUM ARRHYTHMIA; HUMAN; INFECTION; INFLAMMATORY BOWEL DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MUCOSA INFLAMMATION; NONHODGKIN LYMPHOMA; OBESITY; OVERALL SURVIVAL; PEPTIC ULCER; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEPTIC SHOCK; STEM CELL; SURVIVAL RATE; THROMBOCYTOPENIA; VOMITING; ADVERSE EFFECTS; AGE; AUTOTRANSPLANTATION; DISEASE COURSE; FRANCE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LYMPHOMA; MORTALITY; PROGNOSIS; RECURRENT DISEASE; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARMUSTINE; CYTARABINE; DISEASE PROGRESSION; ETOPOSIDE; FEMALE; FRANCE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA; MALE; MELPHALAN; PROGNOSIS; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 84938869049     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2014.1001987     Document Type: Article

References (54)

1. Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin 2014; 64: 9-29.
2. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987-994.
3. Thieblemont C, Coiffier B. Lymphoma in older patients. J Clin Oncol 2007; 25: 1916-1923.
4. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540-1545.
5. Haioun C, Lepage E, Gisselbrecht C, et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol-a groupe dEtude des lymphomes de lAdulte study. J Clin Oncol 2000; 18: 3025-3030.
6. Milpied N, Deconinck E, Gaillard F, et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 2004; 350: 1287-1295.
7. Stiff PJ, Unger JM, Cook JR, Constine LS, Couban S, Stewart DA, et al. Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma. N Engl J Med 2013; 369: 1681-90.
8. Khouri IF, Romaguera J, Kantarjian H, et al. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 1998; 16: 3803-3809.
9. Van't Veer MB, de Jong D, MacKenzie M, et al. High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients. Br J Haematol 2009; 144: 524-530.
10. Geisler CH, Kolstad A, Laurell A, et al. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur. Br J Haematol 2012; 158: 355-362.
11. Dreyling M, Lenz G, Hoster E, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 2005; 105: 2677-2684.
12. Abrey LE, Moskowitz CH, Mason WP, et al. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol 2003; 21: 4151-4156.
13. Colombat P, Lemevel A, Bertrand P, et al. High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group. Bone Marrow Transplant 2006; 38: 417-420.
14. DAmore F, Relander T, Lauritzsen GF, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol 2012; 30: 3093-3099.
15. Mounier N, Gisselbrecht C. Conditioning regimens before transplantation in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol 1998; 9: S15-S21.
16. Jantunen E, Kuittinen T, Penttilä K, et al. High-dose melphalan (200 mg/m2) supported by autologous stem cell transplantation is safe and effective in elderly (> or=65 years) myeloma patients: comparison with younger patients treated on the same protocol. Bone Marrow Transplant 2006; 37: 917-922.
17. Kumar SK, Dingli D, Lacy MQ, et al. Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: results from a matched pair analysis. Am J Hematol 2008; 83: 614-617.
18. Stamatoullas A, Fruchart C, Khalfallah S, et al. Peripheral blood stem cell transplantation for relapsed or refractory aggressive lymphoma in patients over 60 years of age. Bone Marrow Transplant 1997; 19: 31-35.
19. Moreau P, Milpied N, Voillat L, et al. Peripheral blood stem cell transplantation as front-line therapy in patients aged 61 to 65 years: a pilot study. Bone Marrow Transplant 1998; 21: 1193-1196.
20. Jantunen E, Mahlamäki E, Nousiainen T. Feasibility and toxicity of high-dose chemotherapy supported by peripheral blood stem cell transplantation in elderly patients (>/=60 years) with non-Hodgkin's lymphoma: comparison with patients < 60 years treated within the same protocol. Bone Marrow Transplant 2000; 26: 737-741.
21. Gopal AK, Gooley TA, Golden JB, et al. Efficacy of high-dose therapy and autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma in adults 60 years of age and older. Bone Marrow Transplant 2001; 27: 593-599.
22. Bitran JD, Klein L, Link D, et al. High-dose myeloablative therapy and autologous peripheral blood progenitor cell transplantation for elderly patients (greater than 65 years of age) with relapsed large cell lymphoma. Biol Blood Marrow Transplant 2003; 9: 383-388.
23. Magagnoli M, Castagna L, Balzarotti M, et al. Feasibility and toxicity of high-dose therapy (HDT) supported by peripheral blood stem cells in elderly patients with multiple myeloma and non-Hodgkin's lymphoma: survey from a single institution. Am J Hematol 2003; 73: 267-272.
24. Buadi FK, Micallef IN, Ansell SM, et al. Autologous hematopoietic stem cell transplantation for older patients with relapsed non-Hodgkin's lymphoma. Bone Marrow Transplant 2006; 37: 1017-1022.
25. Jantunen E, Itälä M, Juvonen E, et al. Autologous stem cell transplantation in elderly (> 60 years) patients with non-Hodgkin's lymphoma: a nation-wide analysis. Bone Marrow Transplant 2006; 37: 367-372.
26. Gopal AK, Rajendran JG, Gooley TA, et al. High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or=60 years old with relapsed or refractory B-cell lymphoma. J Clin Oncol 2007; 25: 1396-1402.
27. Hosing C, Saliba RM, Okoroji G-J, et al. High-dose chemotherapy and autologous hematopoietic progenitor cell transplantation for non-Hodgkin's lymphoma in patients > 65 years of age. Ann Oncol 2008; 19: 1166-1171.
28. Jantunen E, Canals C, Rambaldi A, et al. Autologous stem cell transplantation in elderly patients (> or=60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registry. Haematologica 2008; 93: 1837-1842.
29. Yusuf RZ, Dey B, Yeap BY, et al. Autologous SCT with a dose-reduced BU and CY regimen in older patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 2009; 43: 37-42.
30. Puig N, Pintilie M, Seshadri T, et al. High-dose chemotherapy and auto-SCT in elderly patients with Hodgkin's lymphoma. Bone Marrow Transplant 2011; 46: 1339-1344.
31. Jantunen E, Canals C, Attal M, et al. Autologous stem-cell transplantation in patients with mantle cell lymphoma beyond 65 years of age: a study from the European Group for Blood and Marrow Transplantation (EBMT). Ann Oncol 2012; 23: 166-171.
32. Chihara D, Izutsu K, Kondo E, et al. High-dose chemotherapy with autologous stem cell transplantation for elderly patients with relapsed/refractory diffuse large B cell lymphoma: a nationwide retrospective study. Biol Blood Marrow Transplant 2014; 20: 684-689.
33. Zallio F, Cuttica A, Caracciolo D, et al. Feasibility of peripheral blood progenitor cell mobilization and harvest to support chemotherapy intensification in elderly patients with poor prognosis: non-Hodgkin's lymphoma. Ann Hematol 2002; 81: 448-453.
34. Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912-2919.
35. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244.
36. Shimoni A, Avivi I, Rowe JM, et al. A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma. Cancer 2012; 118: 4706-4714.
37. Gastaud L. Prévention des infections systémiques à streptocoques viridans par bains de bouche à la vancomycine en soins intensifs d'hématologie. Poster presented at Annual Meeting of the French Society of Bonne Marrow Transplantation and Cellular Therapy, 27-28 October 2011, Paris, France. Available from: sfgm-tc.com/abstractssfgmtc2011poster21.html
38. Thieblemont C, Dumontet C, Saad H, et al. Amifostine reduces mucosal damage after high-dose melphalan conditioning and autologous peripheral blood progenitor cell transplantation for patients with multiple myeloma. Bone Marrow Transplant 2002; 30: 769-775.
39. Italiano A, Chamorey E, Foa C, et al. Amifostine can reduce oral mucositis after high-dose melphalan conditioning in patients with multiple myeloma: a retrospective study. Blood 2004; 104 (Suppl. 1): Abstract 5022.
40. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997; 89: 3909-3918.
41. Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20 + B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008; 9: 105-116.
42. Advani RH, Chen H, Habermann TM, et al. Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E-IPI). Br J Haematol 2010; 151: 143-151.
43. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe dEtude des Lymphomes de lAdulte. J Clin Oncol 2005; 23: 4117-4126.
44. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-383.
45. Jones JA, Qazilbash MH, Shih Y-CT, et al. In-hospital complications of autologous hematopoietic stem cell transplantation for lymphoid malignancies. Cancer 2008; 112: 1096-1105.
46. Plattel WJ, Kluin-Nelemans HC, de Bock GH, et al. Prognostic value of comorbidity for auto-SCT eligibility and outcome in relapsed or refractory aggressive non-Hodgkin's lymphoma. Bone Marrow Transplant 2011; 46: 827-834.
47. Nabhan C, Smith SM, Helenowski I, et al. Analysis of very elderly (≥ 80 years) non-hodgkin lymphoma: impact of functional status and co-morbidities on outcome. Br J Haematol 2012; 156: 196-204.
48. Winkelmann N, Petersen I, Kiehntopf M, et al. Results of comprehensive geriatric assessment effect survival in patients with malignant lymphoma. J Cancer Res Clin Oncol 2011; 137: 733-738.
49. Peyrade F, Gastaud L, Ré D, et al. Treatment decisions for elderly patients with haematological malignancies: a dilemma. Lancet Oncol 2012; 13: e344-e352.
50. Klaus J, Herrmann D, Breitkreutz I, et al. Effect of CD34 + cell dose on hematopoietic reconstitution and outcome in 508 patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Eur J Haematol 2007; 78: 21-28.
51. Morris CL, Siegel E, Barlogie B, et al. Mobilization of CD34 + cells in elderly patients (≥ 70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen. Br J Haematol 2003; 120: 413-423.
52. Blijlevens N, Schwenkglenks M, Bacon P, et al. Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy-European Blood and Marrow Transplantation Mucositis Advisory Group. J Clin Oncol 2008; 26: 1519-1525.
53. Spencer A, Horvath N, Gibson J, et al. Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation. Bone Marrow Transplant 2005; 35: 971-977.
54. Mounier N, El Gnaoui T, Tilly H, et al. Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial. Haematologica 2013; 98: 1726-1731.